
    
      To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when
      administered concurrently with carboplatin and thoracic radiation therapy.

      To determine, qualitatively, the occurrence of local tumor responses identified with this
      regimen.
    
  